Transaxillary transcatheter ACURATE neo aortic valve implantation - The TRANSAX multicenter study.
ACURATE neo
TAVI
TAVR
trans-subclavian
transaxillary
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
01 08 2021
01 08 2021
Historique:
revised:
25
10
2020
received:
22
08
2020
accepted:
29
11
2020
pubmed:
15
12
2020
medline:
21
10
2021
entrez:
14
12
2020
Statut:
ppublish
Résumé
Transcatheter aortic valve replacement (TAVR) via transaxillary (TAx) approach with ACURATE neo valve is an off-label procedure. Our aim was to gather information on ACURATE neo cases implanted via TAx approach and report major outcomes. The TRANSAX Study (NCT04274751) retrospectively gathered patients from nine centres in Europe and North America treated with ACURATE neo valve through TAx approach up to May/2019. Follow up was pre-specified at 1-year and was obtained for all patients. A total of 75 patients (79 ± 10 years; 32% women) were included. Left axillary (72%) and conscious sedation (95.2%) were the most common setting. Risk scores were higher when right axillary artery and surgical cut-down were selected. Severe complications including valve embolization, coronary obstruction, annulus rupture, and procedural mortality did not occur. Cardiac tamponade occurred in two cases (2.7%) with one requiring conversion to open surgery (1.3%). Bail-out stenting and surgical vascular repair were required in 7 (9.3%) and 3 (4%) cases, respectively. The need for new permanent pacemaker was 8%. Procedural success (96%), in-hospital (2.7%), and 1-year mortality (8%) were comparable in all settings. Only one case (1.3%) complicated with cerebrovascular event and one (1.3%) presented moderate aortic regurgitation before discharge. TAx TAVR procedures with the ACURATE neo valve were presented high success rate and low in-hospital and 1-year mortality.
Sections du résumé
BACKGROUND
Transcatheter aortic valve replacement (TAVR) via transaxillary (TAx) approach with ACURATE neo valve is an off-label procedure. Our aim was to gather information on ACURATE neo cases implanted via TAx approach and report major outcomes.
METHODS AND RESULTS
The TRANSAX Study (NCT04274751) retrospectively gathered patients from nine centres in Europe and North America treated with ACURATE neo valve through TAx approach up to May/2019. Follow up was pre-specified at 1-year and was obtained for all patients. A total of 75 patients (79 ± 10 years; 32% women) were included. Left axillary (72%) and conscious sedation (95.2%) were the most common setting. Risk scores were higher when right axillary artery and surgical cut-down were selected. Severe complications including valve embolization, coronary obstruction, annulus rupture, and procedural mortality did not occur. Cardiac tamponade occurred in two cases (2.7%) with one requiring conversion to open surgery (1.3%). Bail-out stenting and surgical vascular repair were required in 7 (9.3%) and 3 (4%) cases, respectively. The need for new permanent pacemaker was 8%. Procedural success (96%), in-hospital (2.7%), and 1-year mortality (8%) were comparable in all settings. Only one case (1.3%) complicated with cerebrovascular event and one (1.3%) presented moderate aortic regurgitation before discharge.
CONCLUSIONS
TAx TAVR procedures with the ACURATE neo valve were presented high success rate and low in-hospital and 1-year mortality.
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
E291-E298Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Brennan JM, Holmes DR, Sherwood MW, et al. The association of transcatheter aortic valve replacement availability and hospital aortic valve replacement volume and mortality in the United States. Ann Thorac Surg. 2014;98:2016-2022.
Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous trans- catheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case de-scription. Circulation. 2002;106:3006-3008.
Kurra V, Schoenhagen P, Roselli EE, et al. Prevalence of significant peripheral artery disease in patients evaluated for percutaneous aortic valve insertion: Preproce- dural assessment with multidetector computed tomography. J Thorac Cardiovasc Surg. 2009;137:1258-1264.
Caceres M, Braud R, Roselli EE. The axillary/subclavian artery access route for transcatheter aortic valve replacement: a systematic review of the literature. Ann Thorac Surg. 2012;93:1013-1018.
Schofer N, Deuschl F, Conradi L, Lubos E, Schirmer J, Reichens- purner H, Blankenberg S, Treede H, Schäfer U. Preferential short cut or alternative route: the transaxillary access for transcatheter aortic valve implantation. J Thorac Dis 2015;7:1543-1547.
Moat NE, Ludman P, DeBelder MA, et al. Mullen long-term outcomes after transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis: the U.K. TAVI (United Kingdom Transcatheter aortic valve implantation) registry. J Am Coll Cardiol. 2011;58:2130-2138.
Amat-Santos IJ, Rojas P, Gutiérrez H, et al. Transubclavian approach: a competitive access for transcatheter aortic valve implantation as compared to transfemoral. Catheter Cardiovasc Interv. 2018;92(5):935-944.
Garcia DC, Benjo A, Cardoso RN, et al. Device stratified comparison among transfemoral, transapical and transubclavian access for Transcatheter aortic valve replacement (TAVR): a meta-analysis. Intern J Cardiol. 2014;172:e318-e321.
Schäfer U, Deuschl F, Schofer N, et al. Safety and efficacy of the percutaneous trans- axillary access for transcatheter aortic valve implantation using Vari- ous transcatheter heart valves in 100 consecutive patients. Int J Cardiol. 2017;232:247-254. https://doi.org/10.1016/j.ijcard.2017.01.010.
Möllmann H, Hengstenberg C, Hilker M, et al. Real-world experience using the ACURATE neo prosthesis: 30-day outcomes of 1,000 patients enrolled in the SAVI TF registry. EuroIntervention. 2018;13:e1764.
Kim WK, Hengstenberg C, Hilker M, et al. The SAVI-TF registry. 1 year outcomes of the European post-market registry using the ACURATE neo Transcatheter heart valve under real-world conditions in 1,000 patients. JACC: Cardiovascular Interventions. 2018;11(14):1368-1374.
Amat-Santos IJ, Gutiérrez H, Sathananthan J, Webb JG. Fracture of small Mitroflow® aortic bioprosthesis following valve-in-valve transcatheter aortic valve replacement with ACURATE neo valve - from bench testing to clinical practice. Catheter Cardiovasc Interv. 2020;95:E120-E122.
Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the valve academic research Consortium-2 consensus document (VARC-2). Eur J Cardiothorac Surg. 2012;42:S45-S60.
Nombela-Franco L, Rodés-Cabau J, DeLarochellière R, et al. Predictive factors, efficacy, and safety of balloon post-dilation after transcatheter aortic valve implantation with a balloon-expandable valve. JACC Cardiovasc Interv. 2012;5:499-512.
Harjai KJ, Bules T, Berger A, et al. Efficiency, safety, and quality of life after transcatheter aortic valve implantation performed with moderate sedation versus general anesthesia. Am J Cardiol. 2020;125:1088-1095.
Lefèvre G, Jégou A, Dambrin G, et al. Comparison of trans-femoral transcatheter aortic valve replacement performed with a minimally invasive simplified technique: "FAST" versus a standard approach. J Invasive Cardiol. 2019;31:300-306.
Amat-Santos IJ, Dumont E, Villeneuve J, et al. Effect of thoracic epidural analgesia on clinical outcomes following transapical transcatheter aortic valve implantation. Heart. 2012;98:1583-1590.